GlobeNewswire Inc.··Hagens BermanuniQure Stock Plunged 49% After FDA Rift—Class Action Deadline Looms for Investors
Hagens Berman investigates $QURE for allegedly misrepresenting FDA interactions on AMT-130 gene therapy. Stock crashed 49% November 3 after FDA disagreement revealed.
QUREstock declineinvestor losses